Abstract P375: Prospective Associations of Accelerometer-measured Physical Activity and Sedentary Time With Cardiometabolic Multimorbidity in the CARDIA Study

Abstract

Background: Cardiometabolic multimorbidity is rising rapidly in the US. This condition is associated with greater health care burden and risk for adverse outcomes, including mortality. We investigated the relations of sedentary time (ST), light intensity physical activity (LPA), and moderate to vigorous intensity physical activity (MVPA) with future cardiometabolic multimorbidity in mid-life. Methods: Participants were 1,863 adults (mean ± SD age=45±4 years, 58% female, 39% Black) from the Coronary Artery Risk Development in Young Adults (CARDIA) study who wore an ActiGraph 7164 accelerometer in 2005-2006 (baseline). Cardiometabolic multimorbidity was defined as ≥2 measured cardiometabolic conditions (untreated/uncontrolled hypertension and hyperlipidemia, diabetes mellitus, chronic kidney disease, and clinical cardiovascular outcomes). Separate logistic regression models provided estimates of prospective associations of accelerometer-measured ST, LPA, and MVPA with cardiometabolic multimorbidity 10 years later in participants with <2 cardiometabolic conditions at baseline. Interactions by age, sex, and race were explored. Results: The highest (>47.3 min/d) vs. lowest (<17.5 min/d) quartile of MVPA was associated with lower odds of cardiometabolic multimorbidity (OR: 0.61; CI: 0.37, 0.99) 10-years later. This association did not differ by age, race, or sex. Overall, there was no association between ST and cardiometabolic multimorbidity. However, a significant interaction was observed by age (p value=0.03). In age-stratified analyses, among participants ≥46 years at baseline, the highest (>9.3 hr/d) vs. lowest (<7.1 hr/d) quartile of ST was associated with higher odds of cardiometabolic multimorbidity (OR: 2.86; CI: 1.36, 6.17). No associations were observed between LPA and cardiometabolic multimorbidity. Conclusions: In mid-life adults with <2 conditions at baseline, greater daily MVPA was associated with lower odds of future cardiometabolic multimorbidity burden 10 years later.